Modern Medicine Feature Articles

Health IT creates lose-lose situation for physicians
Health IT creates lose-lose situation for physiciansPatients are torn between whether they want their physicians to use technology or not.
DAA therapy effective in advanced liver disease in real-world studyAll-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.
DAAs do not increase risk of hepatic decompensation in HCV patientsResearchers say theirs is first national study with a large population to examine possible link.
How to increase your optical capture rateTake these suggestions and you’ll watch your capture rate improve and your average optical ticket rise.
Why do women physicians experience burnout more than men?
Why do women physicians experience burnout more than men?The statistics are clear: Physicians are burned out, miserable and trying to get out of the clinical practice of medicine, and women physicians are leading the pack at twice the level of burnout as their male colleagues.
Research success during residency: Seven useful strategiesUrologic oncology fellow, Ariel Schulman, MD, shares some tips to help residents make research a positive experience.
The poor man’s red/green testOne morning, as a few faculty members were squeezing in a workout before work, the topic arose of how to use the red-green (Duochrome) test most efficiently in clinic.
HS treatment requires multipronged approach
HS treatment requires multipronged approachEvidence supports combined treatments to target the many factors tied to hidradenitis suppurativa. See one expert's recommendations.
Combined therapy targets inflammationResearchers treated a small cohort with two anti-inflammatory drugs and saw a significant improvement in clinical manifestations of disease. Further data showed the approach safely maintained results.
Nitric oxide drug candidate falters in studyNovan, maker of the experimental topical acne treatment SB204, has announced that its nitric oxide-releasing drug achieved statistical significance in only one of three endpoints in one of two phase 3 trials.